Immunitrack provides a complete product and service pipeline to optimize immunogenicity assessments during drug development, as well as a broad portfolio of reagents to monitor patient CD8 and CD4 T cell responses to lead drug candidates during early R&D and clinical trials.
How Can Immunitrack Help R&D?
The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in the manufacture and application of MHC I and II molecules and peptides to accurately study MHC epitope binding through our proprietary NeoScreen® platform.
Major Areas of Application
- Immuno-oncology: selection and study of neo-epitopes for personalized cancer vaccine development.
- Vaccine development: selection of immunogenic epitopes from viral and bacterial targets.
- De-immunisation: reduce the risk of anti-drug antibody development by identifying and removing CD4 T cell epitopes in candidate biologics.
- TCR Off-Target: de-risking candidate TCR and TCR-like therapies.
We produce customized MHC tetramers and peptides to detect and quantify subsets of patient immune (T) cells with specificity towards a given antigen within blood samples.
All of our MHC I reagents are biotinylated and produced on our optimized manufacturing platform, and we guarantee 100% peptide loading of each complex.
Our unique NeoScreen® platform combines more than a decade of world-leading expertise in MHC/epitope binding assays with a high level of automation. The result is a highly scalable and accurate high throughput platform that can screen thousands of (neo-)epitopes for affinity and stability.
Depending on the desired immune response our clients can then select and progress the best candidates through therapeutic development. Our repository is continuously growing, and currently holds more than 70 different MHC I and 20 MHC II alleles.